A
216.47
-0.91 (-0.42%)
| Penutupan Terdahulu | 217.38 |
| Buka | 216.08 |
| Jumlah Dagangan | 730,318 |
| Purata Dagangan (3B) | 708,578 |
| Modal Pasaran | 11,139,495,936 |
| Harga / Pendapatan (P/E Ke hadapan) | 333.33 |
| Harga / Jualan (P/S) | 15.90 |
| Harga / Buku (P/B) | 210.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | -64.39% |
| Margin Operasi (TTM) | -45.67% |
| EPS Cair (TTM) | -5.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 397.02% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | -118.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.98 M |
| Pulangan Atas Aset (ROA TTM) | -26.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -282.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Axsome Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 76.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alethea Capital Management, Llc | 31 Dec 2025 | 668,710 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 251.00 (UBS, 15.95%) | Beli |
| Median | 223.50 (3.25%) | |
| Rendah | 202.00 (Wells Fargo, -6.69%) | Beli |
| Purata | 225.00 (3.94%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 170.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 24 Feb 2026 | 220.00 (1.63%) | Beli | 169.95 |
| RBC Capital | 24 Feb 2026 | 222.00 (2.55%) | Beli | 169.95 |
| UBS | 24 Feb 2026 | 251.00 (15.95%) | Beli | 169.95 |
| Wells Fargo | 24 Feb 2026 | 202.00 (-6.68%) | Beli | 169.95 |
| Wolfe Research | 24 Feb 2026 | 230.00 (6.25%) | Beli | 169.95 |
| Needham | 23 Feb 2026 | 225.00 (3.94%) | Beli | 174.76 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| JACOBSON MARK L. | - | 223.38 | -4,750 | -1,062,426 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,750 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,062,426 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 223.38 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| JACOBSON MARK L. | Pegawai | 05 May 2026 | Jual automatik (-) | 233 | 223.06 | 51,973 |
| JACOBSON MARK L. | Pegawai | 05 May 2026 | Pelaksanaan pilihan | 233 | - | - |
| JACOBSON MARK L. | Pegawai | 04 May 2026 | Jual automatik (-) | 4,517 | 223.70 | 1,010,453 |
| JACOBSON MARK L. | Pegawai | 04 May 2026 | Pelaksanaan pilihan | 4,517 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |